The FDA Sticks With Plan To Exercise Discretion In Enforcing Physician Compounding
Physicians who compound drugs in their offices for patients will not be inspected as FDA decides to exercise discretion, recent final guidance said.
You may also be interested in...
Just how much will the FDA look the other way when it comes to inspecting physician compounders?
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.